X
Xcell Biosciences
Biotech & Life Sciences · San Francisco, United States · Founded 2012
Building products that enable propagation and gene editing in challenging cell types for clinical research and cell therapy applications MoreLess
Xcell Biosciences, based in San Francisco, is a pioneering life science startup focused on advancing cell therapy manufacturing. The company develops cutting-edge systems that enable precise control over primary cell phenotype and function, which is crucial for optimizing the efficacy and persistence of cell therapies. Xcell Biosciences serves clients in the biotechnology and pharmaceutical sectors, particularly those involved in cell therapy research and development. Operating in the highly specialized market of cell therapy, the company employs a business model centered around the sale and licensing of its proprietary technology. Revenue is generated through direct sales of their systems, as well as through partnerships and collaborations with other biotech firms.
Keywords: cell therapy, biotechnology, pharmaceutical, primary cell control, efficacy optimization, persistence enhancement, proprietary technology, life science, startup, San Francisco.
Company overview
Xcell Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- San Francisco, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 61.2
Valuation & funding
Xcell Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2024 | $0 | — | LabCorp | ↗ |
| SERIES BOther financing | Jan 2022 | $28M | $110M | LabCorp · Viking Global Investors · Casdin Capital · Dynamk Capital | ↗ |
| LATE VCOther financing | Sep 2021 | $15M | $62M | Undisclosed | — |
| SERIES AOther financing | Feb 2017 | $12M | $48M | HBM Genomics · Viking Global Investors · HBM Healthcare Investments | — |
| SEEDOther financing | Nov 2015 | $5M | $20M | Lightspeed Venture Partners · Viking Global Investors · HBM Partners | — |
| EARLY VCOther financing | May 2015 | Undisclosed | — | ||
| CONVERTIBLEOther financing | Oct 2014 | Undisclosed | — | ||
| FundingOther financing | Jun 2014 | Berkeley SkyDeck Accelerator | — | ||
| SPINOUTOther financing | Jan 2012 | Berkeley Lab · University of California, Berkeley | — |
Growth signals
Xcell Biosciences website traffic
Latest recorded traffic for Xcell Biosciences is 1.6K monthly website visits, down 27.3% over the last three months. Xcell Biosciences's team declined 41.4% over the past year.
Comparisons
Xcell Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Xcell Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Xcell Biosciences has talent and traffic
team presence
In the news
Latest news about Xcell Biosciences
Recent press, funding announcements, and product moves mentioning Xcell Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Xcell Biosciences
An AI-synthesized read of the highest-engagement posts about Xcell Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xcell Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.